Heatwurx (NASDAQ:PCSA) Stock Rating Upgraded by Wall Street Zen

Heatwurx (NASDAQ:PCSA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Several other equities analysts also recently commented on PCSA. HC Wainwright decreased their price target on shares of Heatwurx from $50.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, September 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a report on Wednesday, October 8th. Finally, Zacks Research cut shares of Heatwurx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Heatwurx presently has an average rating of “Hold” and a consensus target price of $25.00.

Heatwurx Trading Down 3.1%

Shares of NASDAQ PCSA opened at $3.78 on Friday. The firm has a market cap of $8.58 million, a P/E ratio of -0.11 and a beta of 1.09. The business’s 50 day moving average is $7.34 and its 200-day moving average is $6.36. Heatwurx has a 1-year low of $2.74 and a 1-year high of $27.00.

Heatwurx (NASDAQ:PCSA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.75) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.25. Analysts forecast that Heatwurx will post -4.05 EPS for the current year.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.